The Market Online Video

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Recce Pharmaceuticals (ASX:RCE) has confirmed its completion of the latest study using its R327 anti-infective as…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…